Lpl Financial LLC Verve Therapeutics, Inc. Transaction History

Lpl Financial LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 12, 2025	BUY	$2.97 - $11.38 $37,413 - $143,353	12,597 New	12,597 $141,000
Q4 2024 Feb 11, 2025	BUY	$4.5 - $7.19 $82,269 - $131,447	18,282 Added 94.5%	37,629 $212,000
Q3 2024 Nov 08, 2024	BUY	$4.4 - $7.86 $27,755 - $49,580	6,308 Added 48.38%	19,347 $93,000
Q2 2024 Aug 07, 2024	SELL	$4.76 - $12.79 $149,102 - $400,633	-31,324 Reduced 70.61%	13,039 $63,000
Q1 2024 May 10, 2024	BUY	$10.81 - $17.96 $479,564 - $796,759	44,363 New	44,363 $589,000

8.51M

2.9K

37.1K

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $667M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

Get notified when there are updates to the investment portfolio of Lpl Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Lpl Financial LLC with notifications on news.